EP0831841A1 - Means for treating radiation injuries - Google Patents

Abstract

The description relates to the use of phosphoric derivatives of alkaloids of general formula (I), as published in AT-PS 377 988 and in AT-PS 354 644, for producing a medicament for the treatment or prevention of radiation injuries.

Description

 Radiation damage treatment agents

The present invention relates to the use of phosphorus derivatives of alkaloids for the production of a medicament for the treatment of radiation damage.

AT-PS-377 988 and AT-PS-354 644 describe processes for the preparation of new phosphorus derivatives of alkaloids or of new salts of alkaloid derivatives of thiophosphoric acid. Such compounds have a pharmacological activity and can be used as cytostatics.

It has now surprisingly been found that the phosphorus derivatives of alkaloids disclosed in AT-PS 377 988 and AT-PS 354 644 can be used for the production of medicaments for the treatment of radiation damage and also for the prophylaxis of the radiation exposure to be expected.

Process for the preparation of phosphorus derivatives of alkaloids of the general formula (I)

wherein m and n = 1, 2 or 3; R ¹ , R ² and R ³ each independently represent H or methoxy, where R ¹ and R * or R ² and R ³ together can also represent a methylenedioxy group;

R ⁴ and R ^{5 '} together with the carbon atoms to which they adhere form an optionally fully or partially hydrogenated phenyl or naphthyl group, which in turn can be substituted by methoxy, hydroxy or dioxymethyl, where R ^{7 is} H or = 0 or one over a -CH ₂ -CO-CH _? -Chain bound same

SPARE BLADE (RULE 26) Is ring system, R ⁶ -CH ₃ and double bonds in position 1, 2 and / or 7, 8 may be present; or

R ⁶ and R ⁷ together with the C and N atoms to which they adhere form an optionally hydrogenated benzo or naphthoring system, which in turn can be substituted by methoxy, oxo, methyl or dioxymethyl groups, the CN -Binding in position 1, 2 may be absent and R ⁴ and R ^{5 are} H;

R 1 represents 2H, -CH ₂ -CH ₂ -, H or -CH ₂ -CH ₂ C1;

X is 0 or N;

R ⁸ + R ⁹ and R 1 1 12 -CH -CH.- mean and, if Y = S, X

= N and n = 2, R ² and R ³ -CH ₂ -CH ₂ -, -CH ₂ -CH ₂ -0-CH ₂ -CH. or -CH ₂ -CH ₂ -N-CH ₂ -CH ₂ -; if

CH.

represents; Y

Y = 0, X = N, n means;

Y = 0, X = N, n; and if

Y = 0, X = 0, n = 1,

R ⁸ and R ⁹ each mean -CH ₂ -CH ₂ -C1, R ^Ü H ₂ and R ¹¹ + R ¹² -CH ₂ -CH ₂ - or -CH ₂ -CH ₂ -CH ₂ - if Y = S, X = N, R ³ -CH ₂ -CH ₂ -, and their salts with pharmaceutically acceptable acids, are known from AT-PS 377 988; the preparation of alkoid derivatives of thiophosphoric acid of the general formula

REPLACEMENT BLAπ (RULE 26) wherein n is 1, 2 or 3; m represents 1, 2 or 3; R ¹ , R ² and R ³ each independently mean hydrogen or methoxy, where R ¹ and R ² or R ² and R ³ together can also represent a methylene dioxy group; R ^{4 represents} hydrogen, hydroxy or methyl; and, if R ^{6 is} hydrogen, R ⁵ and R ⁷ together form the group

form; or, if R ^{7 represents} a methyl group, the groups R ^s and R ⁶ the group

represent; and in position 1, 8 and / or 2, 3 there can be a double bond; and A represents a monovalent or the equivalent part of a multivalent anion is disclosed in AT-PS 354 644.

According to a particularly preferred embodiment of the present invention, the reaction product of the alkaloids of Chelidonium aijus L. with thiophosphoric triaziridide is used for

REPLACEMENT BLADE (RULE 26) Provision of a drug used for the treatment or prophylaxis of radiation damage.

For the sake of simplicity, this implementation product is referred to below as "Ukrain".

The surprising effect of Ukrain in the treatment or prophylaxis of radiation damage is demonstrated below using case descriptions.

The Chernobyl syndrome is often described in the literature. In addition to an increased cancer and malformation rate in adults, children and at that time not yet born, clinical pictures were reported which indicate deregulation of the immune system. It is known that strong radiation exposure to the organism leads to a variety of similar symptoms.

Case descriptions:

1.N.N., female, 8 years old, born in Kiev, 6 months after the reactor accident. Normal birth course; delayed general development; slow weight gain despite optimal food supply. Blood count still within the norm, increased depression (16/38), sickly. In 1994 a Ukrainian course, 5 ml Ukrain orally with the main meal every 3 days, was prescribed 10 times. Noticeable improvement in general condition, reduction within the norm.

2.K.K., male, 11 years old, lives near Kiev. At the age of 3 years, the general condition deteriorated noticeably. Iodine 131 damage to the thyroid gland is diagnosed

- "Grade 2". Serum toxoplasmic antibodies. Therapy improves the general condition somewhat and the toxoplasmic antigen titer decreases. Ukrain, 5 ml, administered orally every second day, visibly improves the general condition of the patient, after 2 x 10 ampoules with a 20 day break in between. A scintillogram of the thyroid shows little deviations from the norm. 3. LL, male, 7 years old, "Posttschernobyl-child"; Grade 2- changes in thyroid gland, uncontrollable Giardia lamblia infection with signs of general immunodeficiency with recurrent banal infections. After a cure with 10 ml 5 ml Ukrain in the rapid improvement of the general condition. The lambliasis is no longer detectable after treatment. Thyroid values on the edge of the norm.

The medicaments produced according to the invention preferably consist of an aqueous solution of the alkaloid phosphorus derivatives used or their salts, optionally together with other auxiliaries known per se. The drug according to the invention is preferably administered by injection, for example intraperitoneally, intramuscularly or intravenously, the dosage depending on the case and being related to the severity of the disease to be treated and the condition of the patient.

In any case, it is within the specialist knowledge of the attending physician to determine a suitable dosage from case to case.

Claims

Patent claims:

1 . Use of phosphorus derivatives of alkaloids of the general formula (I)

wherein m and n = 1, 2 or 3; R ¹ , R ² and R ³ each independently represent H or methoxy, where R ¹ and R ² or R ² and R ³ together can also represent a methylenedioxy group;

R ⁴ and R ⁵ together with the carbon atoms to which they adhere form an optionally fully or partially hydrogenated phenyl or naphthyl group, which in turn can be substituted by methoxy, hydroxy or dioxymethyl, where R ^{7 is} H or = 0 or one is the same ring system bonded via a -CH ₂ -CO-CH ₂ chain, R ^{6 is} -CH ₃ and double bonds in position 1, 2 and / or 7, 8 may be present; or

R ⁶ and R ⁷ together with the C and N atoms to which they adhere form an optionally hydrogenated benzo or naphthoring system, which in turn can be substituted by methoxy, oxo, methyl or dioxymethyl groups, the CN -Binding in position 1, 2 may be absent and R ⁴ and R ^{5 are} H;

R ¹⁰ = 2H, -CH ₂ -CH ₂ -, H or -CH ₂ -CH ₂ C1;

R ⁸ + R ⁹ and R ¹¹ + R ² -CH ₂ -CH ₂ - mean and, if Y = S, X = N and n = 2, R ² and R ³ -CH ₂ -CH ₂ -, -CH ₂ -CH ₂ -0-CH ₂ -CH ₂ -, or -CH ₂ -CH ₂ -N-CH ₂ -CH ₂ -; if

I CH ₃

or (-C ₂ H ₅ ) ₂ ,

d

= 0, X = N, n = 2, R ² and; and if

Y = O, X = 0, n = 1,

R ⁸ and R ⁹ each mean -CH ₂ -CH ₂ -C1, R ¹⁰ H ₂ and R ¹¹ + R ¹² -CH ₂ -CH ₂ - or -CH ₂ -CH ₂ -CH ₂ - if Y = S, X = N, R ³ -CH ₂ -CH ₂ -, and their salts with pharmaceutically acceptable acids, for the manufacture of a medicament for the treatment or prophylaxis of radiation damage.

2. Use according to claim 1, characterized in that the alkaloid derivatives of thio-phosphoric acid of the general formula as the phosphorus derivatives of alkaloids

wherein n is 1, 2 or 3; m represents 1, 2 or 3; R ¹ , R ² and R ³ each independently represent hydrogen or methoxy

REPLACEMENT BLAπ (RULE 26) - o - ten, where R ¹ and R ² or R ² and R ³ together can also represent a methylene dioxy group; R ^{4 represents} hydrogen, hydroxy or methyl; and when R ^{6 is} hydrogen, R ⁵ and R ⁷ together form the group

form; or, if R ^{7 represents} a methyl group, the groups R ⁵ and R ⁶ the group

represent; and in position 1, 8 and / or 2, 3 there can be a double bond; and A denotes a monovalent or the equivalent part of a polyvalent anion.

3. Use according to claim 1 or 2, characterized in that the reaction product of the alkaloids of Chelidonium maijus L. with thiophosphoric triaziridide is used.

4. Use according to one of claims 1 to 3, characterized gekenn¬ characterized in that a medicament for the treatment or prophylaxis of radiation damage is produced.

ERSÄΓZBLÄTT (REGEL26)